市場調査レポート

商品コード

がん治療薬の世界市場規模、シェア、産業動向分析レポート：適応症別、薬剤クラス別、地域別展望と予測、2023年～2030年

Global Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

出版日: 2023年11月30日 | 発行: KBV Research

| ページ情報: 英文 306 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,600 568,440円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,320 682,128円

レポートPDFを同一企業内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprisewide License)

USD 6,048 954,979円

レポートPDFを同一企業のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

がん治療薬市場規模は2030年までに2,733億米ドルに達し、予測期間中にCAGR 7.7%の市場成長率で上昇すると予測されます。

KBV Cardinalのマトリックスに掲載された分析によると、がん治療薬市場ではファイザーが先行しています。例えば、2022年9月、ファイザーはサイトー・リーズンとの提携を延長し、サイトー・リーズンの人工知能技術をファイザーの医薬品開発プログラムに使用することになっています。この契約では、ファイザーは2,000万米ドルの出資を行い、サイトーリーズンのプラットフォームと疾患モデルのライセンスオプションと、今後5年間で最大1億1,000万米ドルのプロジェクト支援資金を提供します。AbbVie, Inc.、Johnson &Johnson、F. Hoffmann-La Roche Ltd.などの企業がこの市場における主要なイノベーターです。

COVID-19の影響分析

COVID-19パンデミックはがん治療薬市場に大きな影響を与えました。パンデミックは世界の医薬品の製造とサプライチェーンの混乱を招いた。ロックダウン、渡航制限、労働力不足により、がん治療薬の生産と流通が妨げられました。多くの製薬会社が原材料の確保、完成品の輸送、定期的な生産スケジュールの維持という課題に直面し、抗がん剤の供給不足や遅延の可能性が生じた。臨床試験は、新たながん治療薬の上市に極めて重要な役割を果たします。このような研究活動の中断は、新規がん治療薬の開発と承認を遅らせる。がん治療薬市場は、世界がパンデミック後の局面に向かう中、レジリエンス（回復力）プランニングに取り組んでいます。これには、将来の混乱を緩和し、サプライチェーンの堅牢性を高め、不測の課題に対するヘルスケアシステムの適応性を向上させる戦略が含まれます。

市場成長要因

世界のがん罹患率の上昇

例えば、WHOによると、がんは世界規模での主要な死因であり、2020年には約1,000万人が死亡するとされています。2020年には、乳がん（226万例）、肺がん（221万例）、結腸・直腸がん（193万例）、前立腺がん（141万例）、表皮がん（メラノーマを除く120万例）、胃がん（109万例）が大半を占める。がん検診技術や啓発プログラムの進歩により、がんの早期発見が増加しています。早期診断の結果、より効果的な治療法が選択されることが多く、がん治療薬の需要を牽引しています。患者支援団体や教育的イニシアティブによって促進されたがんに対する意識の高まりは、危険因子、初期症状、時宜を得た医療介入の重要性に対する理解を向上させました。このような意識は、がん管理への積極的なアプローチに寄与し、効果的ながん治療薬の需要を促進しています。世界のがん患者数の増加は、同市場に大きな影響を及ぼしています。

世界の老人人口の急増

しかしWHOは、2030年までに6人に1人が60歳以上になると推定しています。2020年までに、60歳以上の人口の割合は10億人から14億人に増加します。60歳以上の世界人口は、2050年までに2倍の21億人になると予測されています。高齢者層は、がんに関連した症状や治療による副作用の負担が大きくなることが多いです。症状に対処し、QOLを改善し、緩和ケアを提供するがん治療薬は、高齢者のがんケアに不可欠な要素となります。アドボカシー活動とともに、遺伝的集団におけるがんに対する意識の高まりは、高齢がん患者が直面する特有の課題に対する理解を深めることにつながっています。この認識は、オーダーメイドの薬物療法を中心とした、より包括的ながん治療へのアプローチに寄与しています。世界の高齢者人口の急増は、がん治療薬市場を大幅に拡大し、高齢者のがん患者を対象とした専門的な治療法の開拓を必要としています。

市場抑制要因

抗がん剤使用に伴う副作用。

多くの抗がん剤は健康な組織に毒性を引き起こす可能性があり、吐き気、嘔吐、疲労、脱毛などの副作用を引き起こします。これらの毒性の重篤度は様々であり、これらを効果的に管理することは、患者の快適さと治療レジメンの遵守を確保するために極めて重要です。ある種の抗がん剤、特に化学療法は免疫系を抑制し、患者を感染症に敏感にさせることがあります。一部の抗がん剤、特に特定の化学療法や標的療法は心臓に悪影響を及ぼし、心毒性を引き起こすことがあります。長期的な心血管合併症を予防するためには、心毒性のモニタリングと管理が不可欠です。抗がん剤の副作用は患者に大きな心理社会的影響を及ぼす可能性があり、不安、抑うつ、身体イメージの変化につながります。がん治療における心理社会的要因に対処することは、全人的な患者支援にとって極めて重要です。これらの要因は、今後数年間の市場成長を低下させると思われます。

適応症の展望

適応症に基づき、市場は肺がん、胃がん、大腸がん、乳がん、前立腺がん、肝臓がん、食道がん、子宮頸がん、腎臓がん、膀胱がん、その他のがんに細分化されます。肺がんセグメントは、2022年の市場で大きな収益シェアを獲得しました。肺がんにおける腫瘍治療薬の使用は、進行中の研究や臨床試験と密接に結びついています。がん治療薬は肺がん治療の状況を大きく改善しました。標的療法から免疫療法、併用療法に至るまで、これらの薬剤は肺がんの複雑性に対処し、患者の転帰改善に寄与するさまざまな利点を提供しています。現在進行中の精密医療の進化と革新的な治療法の開発により、肺がん治療のさらなる進歩が期待されます。

薬剤クラス別の展望

薬剤クラス別では、市場は化学療法、標的療法、免疫療法（生物学的療法）、ホルモン療法に区分されます。2022年には、標的療法分野が腫瘍治療薬市場で最大の売上シェアを占めました。これは、がん細胞の分子標的が特定されたこと、副作用が少ないこと、複数の標的治療薬が利用可能になったことに起因します。最近の細胞技術の発展により、腫瘍細胞とその代謝の分子理解が進み、がん治療のための標的薬物療法の需要が高まっています。一方、免疫療法については、その有効性とパイプライン免疫療法の上市が期待されることから、予測期間中に最も急速な市場成長が見込まれています。

地域別展望

地域別では、市場は北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカに分けられます。アジア太平洋地域は、2022年の同市場においてかなりの収益シェアを獲得しました。同地域の高齢化率の急上昇と、特に新興国市場におけるヘルスケア施設の改善に対する需要の高まりが、市場促進要因の一部となっています。インドや中国のような大手製薬企業の存在も、この地域の市場成長を後押しします。中国は、同地域のヘルスケア施設の改善に対する政府支出の増加や、同国内での高品質医薬品の生産強化に向けた政府のイニシアチブに起因しています。

世界の乳がん市場：地域別
世界の前立腺がん市場：地域別
世界の肺がん市場：地域別
世界の胃がん市場：地域別
世界の結腸直腸がん市場：地域別
世界の肝がん市場：地域別
世界の食道がん市場：地域別
世界の子宮頸がん市場：地域別
世界の腎臓がん市場：地域別
世界の膀胱がん市場：地域別
世界のその他のがん市場：地域別

第6章世界のがん治療薬市場：薬剤クラス別

世界の標的療法市場：地域別
世界の免疫療法（生物学的療法）市場：地域別
世界の化学療法市場：地域別
世界のホルモン療法市場：地域別

第7章世界のがん治療薬市場：地域別

北米
- 北米の市場：国別
  - 米国
  - カナダ
  - メキシコ
  - その他の北米
欧州
- 欧州の市場：国別
  - ドイツ
  - 英国
  - フランス
  - ロシア
  - スペイン
  - イタリア
  - その他の欧州
アジア太平洋
- アジア太平洋の市場：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - シンガポール
  - マレーシア
  - その他のアジア太平洋
ラテンアメリカ・中東・アフリカ
- ラテンアメリカ・中東・アフリカの市場：国別
  - ブラジル
  - アルゼンチン
  - アラブ首長国連邦
  - サウジアラビア
  - 南アフリカ
  - ナイジェリア
  - その他のラテンアメリカ・中東・アフリカ

第8章企業プロファイル

AbbVie, Inc
Amgen, Inc
Astellas Pharma, Inc
AstraZeneca PLC
Bristol Myers Squibb Company
F Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co, Inc.
Pfizer, Inc

第9章がん治療薬市場の勝利の必須条件

図表

LIST OF TABLES

TABLE 1 Global Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 Global Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions- Oncology Drugs Market
TABLE 5 Acquisition and Mergers- Oncology Drugs Market
TABLE 6 Global Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 Global Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 Global Breast Cancer Market by Region, 2019 - 2022, USD Million
TABLE 9 Global Breast Cancer Market by Region, 2023 - 2030, USD Million
TABLE 10 Global Prostate Cancer Market by Region, 2019 - 2022, USD Million
TABLE 11 Global Prostate Cancer Market by Region, 2023 - 2030, USD Million
TABLE 12 Global Lung Cancer Market by Region, 2019 - 2022, USD Million
TABLE 13 Global Lung Cancer Market by Region, 2023 - 2030, USD Million
TABLE 14 Global Stomach Cancer Market by Region, 2019 - 2022, USD Million
TABLE 15 Global Stomach Cancer Market by Region, 2023 - 2030, USD Million
TABLE 16 Global Colorectal Cancer Market by Region, 2019 - 2022, USD Million
TABLE 17 Global Colorectal Cancer Market by Region, 2023 - 2030, USD Million
TABLE 18 Global Liver Cancer Market by Region, 2019 - 2022, USD Million
TABLE 19 Global Liver Cancer Market by Region, 2023 - 2030, USD Million
TABLE 20 Global Esophagus Cancer Market by Region, 2019 - 2022, USD Million
TABLE 21 Global Esophagus Cancer Market by Region, 2023 - 2030, USD Million
TABLE 22 Global Cervical Cancer Market by Region, 2019 - 2022, USD Million
TABLE 23 Global Cervical Cancer Market by Region, 2023 - 2030, USD Million
TABLE 24 Global Kidney Cancer Market by Region, 2019 - 2022, USD Million
TABLE 25 Global Kidney Cancer Market by Region, 2023 - 2030, USD Million
TABLE 26 Global Bladder Cancer Market by Region, 2019 - 2022, USD Million
TABLE 27 Global Bladder Cancer Market by Region, 2023 - 2030, USD Million
TABLE 28 Global Other Cancer Market by Region, 2019 - 2022, USD Million
TABLE 29 Global Other Cancer Market by Region, 2023 - 2030, USD Million
TABLE 30 Global Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 Global Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 Global Targeted Therapy Market by Region, 2019 - 2022, USD Million
TABLE 33 Global Targeted Therapy Market by Region, 2023 - 2030, USD Million
TABLE 34 Global Immunotherapy (Biologic Therapy) Market by Region, 2019 - 2022, USD Million
TABLE 35 Global Immunotherapy (Biologic Therapy) Market by Region, 2023 - 2030, USD Million
TABLE 36 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
TABLE 37 Global Chemotherapy Market by Region, 2023 - 2030, USD Million
TABLE 38 Global Hormonal Therapy Market by Region, 2019 - 2022, USD Million
TABLE 39 Global Hormonal Therapy Market by Region, 2023 - 2030, USD Million
TABLE 40 Global Oncology Drugs Market by Region, 2019 - 2022, USD Million
TABLE 41 Global Oncology Drugs Market by Region, 2023 - 2030, USD Million
TABLE 42 North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 North America Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 47 North America Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 48 North America Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 49 North America Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 50 North America Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 51 North America Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 52 North America Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 53 North America Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 54 North America Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 55 North America Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 56 North America Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 57 North America Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 58 North America Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 59 North America Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 60 North America Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 61 North America Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 62 North America Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 63 North America Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 64 North America Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 65 North America Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 66 North America Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 67 North America Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 68 North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 69 North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 70 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 71 North America Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 72 North America Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 73 North America Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 74 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 75 North America Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 76 North America Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 77 North America Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 78 North America Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 79 North America Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 80 US Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 81 US Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 82 US Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 83 US Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 84 US Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 85 US Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 86 Canada Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 87 Canada Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 88 Canada Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 89 Canada Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 90 Canada Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 91 Canada Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 92 Mexico Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 93 Mexico Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 94 Mexico Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 95 Mexico Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 96 Mexico Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 97 Mexico Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 98 Rest of North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 99 Rest of North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 100 Rest of North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 101 Rest of North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 102 Rest of North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 103 Rest of North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 104 Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 105 Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 106 Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 107 Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 108 Europe Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 109 Europe Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 110 Europe Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 111 Europe Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 112 Europe Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 113 Europe Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 114 Europe Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 115 Europe Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 116 Europe Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 117 Europe Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 118 Europe Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 119 Europe Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 120 Europe Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 121 Europe Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 122 Europe Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 123 Europe Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 124 Europe Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 125 Europe Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 126 Europe Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 127 Europe Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 128 Europe Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 129 Europe Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 130 Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 131 Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 132 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 133 Europe Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 134 Europe Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 135 Europe Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 136 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 137 Europe Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 138 Europe Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 139 Europe Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 140 Europe Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 141 Europe Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 142 Germany Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 143 Germany Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 144 Germany Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 145 Germany Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 146 Germany Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 147 Germany Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 148 UK Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 149 UK Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 150 UK Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 151 UK Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 152 UK Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 153 UK Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 154 France Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 155 France Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 156 France Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 157 France Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 158 France Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 159 France Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 160 Russia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 161 Russia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 162 Russia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 163 Russia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 164 Russia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 165 Russia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 166 Spain Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 167 Spain Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 168 Spain Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 169 Spain Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 170 Spain Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 171 Spain Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 172 Italy Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 173 Italy Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 174 Italy Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 175 Italy Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 176 Italy Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 177 Italy Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 178 Rest of Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 179 Rest of Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 180 Rest of Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 181 Rest of Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 182 Rest of Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 183 Rest of Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 184 Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 185 Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 186 Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 187 Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 188 Asia Pacific Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 189 Asia Pacific Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 190 Asia Pacific Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 191 Asia Pacific Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 192 Asia Pacific Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 193 Asia Pacific Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 194 Asia Pacific Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 195 Asia Pacific Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 196 Asia Pacific Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 197 Asia Pacific Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 198 Asia Pacific Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 199 Asia Pacific Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 200 Asia Pacific Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 201 Asia Pacific Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 202 Asia Pacific Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 203 Asia Pacific Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 204 Asia Pacific Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 205 Asia Pacific Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 206 Asia Pacific Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 207 Asia Pacific Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 208 Asia Pacific Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 209 Asia Pacific Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 210 Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 211 Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 212 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 213 Asia Pacific Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 214 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 215 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 216 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 217 Asia Pacific Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 218 Asia Pacific Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 219 Asia Pacific Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 220 Asia Pacific Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 221 Asia Pacific Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 222 China Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 223 China Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 224 China Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 225 China Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 226 China Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 227 China Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 228 Japan Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 229 Japan Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 230 Japan Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 231 Japan Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 232 Japan Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 233 Japan Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 234 India Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 235 India Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 236 India Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 237 India Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 238 India Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 239 India Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 240 South Korea Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 241 South Korea Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 242 South Korea Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 243 South Korea Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 244 South Korea Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 245 South Korea Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 246 Singapore Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 247 Singapore Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 248 Singapore Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 249 Singapore Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 250 Singapore Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 251 Singapore Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 252 Malaysia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 253 Malaysia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 254 Malaysia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 255 Malaysia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 256 Malaysia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 257 Malaysia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 258 Rest of Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 259 Rest of Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 260 Rest of Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 261 Rest of Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 262 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 263 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 264 LAMEA Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 265 LAMEA Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 266 LAMEA Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 267 LAMEA Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 268 LAMEA Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 269 LAMEA Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 270 LAMEA Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 271 LAMEA Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 272 LAMEA Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 273 LAMEA Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 274 LAMEA Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 275 LAMEA Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 276 LAMEA Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 277 LAMEA Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 278 LAMEA Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 279 LAMEA Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 280 LAMEA Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 281 LAMEA Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 282 LAMEA Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 283 LAMEA Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 284 LAMEA Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 285 LAMEA Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 286 LAMEA Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 287 LAMEA Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 288 LAMEA Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 289 LAMEA Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 290 LAMEA Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 291 LAMEA Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 292 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 293 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 294 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 295 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 296 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 297 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 298 LAMEA Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 299 LAMEA Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 300 LAMEA Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 301 LAMEA Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 302 Brazil Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 303 Brazil Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 304 Brazil Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 305 Brazil Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 306 Brazil Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 307 Brazil Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million

The Global Oncology Drugs Market size is expected to reach $273.3 billion by 2030, rising at a market growth of 7.7% CAGR during the forecast period.

Advances in understanding stomach cancer's molecular and genetic characteristics enable the development of more personalized and individualized treatment plans. Consequently, the Stomach Cancer segment captured $13,239.3 million revenue in the market in 2022. Stomach cancer remains a significant global health concern, and efforts in early detection, research, and advancements in treatment modalities are critical for improving outcomes for individuals affected by this disease. Regular screenings, awareness of risk factors, and prompt medical attention for persistent symptoms can contribute to early diagnosis and better treatment outcomes. Oncologists can tailor therapy based on the specific profile of the patient's cancer, optimizing the chances of treatment success.

The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2023, Merck & Co., Inc. collaborations with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., to produce novel clinical development drug candidates with first-in-class and best-in-class potential in oncology, neurology, and immunology. Additionally, In June, 2023, Astellas Pharma Inc. and Cullgen Inc. came into collaboration to develop targeted protein degraders by combining Cullgen's uSMITE platform with novel E3 ligands and Astellas' drug discovery capabilities.

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer Inc. is the forerunners in the Oncology Drugs Market. For Instance, In September, 2022, Pfizer extended its partnership with CytoReason, to use CytoReason's artificial intelligence technology for Pfizer's drug development programs. Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason's platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years. Companies such as AbbVie, Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. are some of the key innovators in the Market.

COVID-19 Impact Analysis

The COVID-19 pandemic had significantly influenced the oncology drugs market. The pandemic led to disruptions in the manufacturing and supply chains of pharmaceuticals globally. Lockdowns, travel restrictions, and workforce shortages impeded the production and distribution of oncology drugs. Many pharmaceutical companies faced challenges in securing raw materials, transporting finished products, and maintaining regular production schedules, leading to potential shortages and delays in the availability of cancer medications. Clinical trials play a pivotal role in bringing new oncology drugs to market. This interruption in research activities delayed the developing and approval of novel cancer therapies. The oncology drugs market is engaged in resilience planning as the world moves toward a post-pandemic phase. This involves strategies to mitigate future disruptions, enhance supply chain robustness, and improve the adaptability of healthcare systems to unforeseen challenges.

Market Growth Factors

Rise in the prevalence of cancer globally

For Instance, Cancer is the primary cause of death on a global scale, accounting for nearly 10 million deaths in 2020, according to the WHO. In 2020, the following cancer types accounted for the majority of cases: breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), epidermis (1.20 million cases excluding melanoma), and stomach (1.09 million cases). Advances in cancer screening technologies and awareness programs have led to increased early detection of cancer. Early diagnosis often results in more effective treatment options, driving the demand for oncology drugs. Heightened awareness about cancer, facilitated by patient advocacy groups and educational initiatives, has improved understanding of risk factors, early symptoms, and the importance of timely medical intervention. This awareness contributes to a proactive approach to cancer management, driving the demand for effective oncology drugs. The rise in the number of cancers globally has profound implications for the market.

Surge in the global geriatric population

However, WHO estimates that by 2030, one in every six individuals will be sixty or older. By 2020, the proportion of the population aged 60 and older will have increased from one billion to 1.4 billion. The global population of individuals 60 and above is projected to increase twofold to 2.1 billion by 2050. The senior population often experiences a higher burden of cancer-related symptoms and side effects of therapy. Oncology drugs that address symptoms, improve quality of life, and provide palliative care become essential components of cancer care for older adults. Increased awareness about cancer in the genetic population, along with advocacy efforts, has led to a greater comprehension of the unique challenges faced by older cancer patients. This awareness contributes to a more comprehensive approach to cancer care, focusing on tailored drug therapies. The surge in the global geriatric population significantly expands the oncology drugs market, necessitating the development of targeted and specialized treatments for older adults with cancer.

Market Restraining Factors

Adverse effects associated with the usage of cancer drugs.

Many cancer drugs can cause toxicity in healthy tissues, leading to adverse effects such as nausea, vomiting, fatigue, and hair loss. The severity of these toxicities can vary and managing them effectively is crucial to ensure patient comfort and compliance with treatment regimens. Certain cancer drugs, particularly chemotherapy, can suppress the immune system, making patients more sensitive to infections. Some cancer drugs, particularly certain chemotherapies, and targeted therapies, can have adverse effects on the heart, leading to cardiotoxicity. Monitoring and managing cardiotoxicity are essential to prevent long-term cardiovascular complications. Adverse effects of cancer drugs can have a significant psychosocial impact on patients, leading to anxiety, depression, and changes in body image. Addressing the psychosocial factors of cancer care is crucial for holistic patient support. These factors will decline the market growth in the coming years.

Indication Outlook

Based on indication, the market is fragmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancer. The lung cancer segment garnered a significant revenue share in the market in 2022. The use of oncology drugs in lung cancer is closely tied to ongoing research and clinical trials. Oncology drugs have significantly improved the landscape of lung cancer treatment. From targeted therapies to immunotherapies and combination regimens, these drugs offer a range of benefits that address the complexities of lung cancer and contribute to better patient outcomes. The ongoing evolution of precision medicine and the development of innovative therapies hold promise for further advancements in lung cancer treatment.

Drug Class Type Outlook

On the basis of drug class type, the market is segmented into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. In 2022, the targeted therapy segment dominated the oncology drugs market with maximum revenue share. This is attributed to identifying molecular targets of cancer cells, fewer adverse effects, and the availability of several targeted therapeutics. Recent developments in cellular technology have enhanced the molecular comprehension of tumor cells and their metabolism, thereby increasing the demand for targeted drug therapies to treat cancer. On the contrary, market growth is anticipated to be most rapid in the need for immunotherapy over the projected period, owing to its efficacy and the expected launch of pipeline immunotherapies.

Regional Outlook

Region-wide, the market is further divided into North America, Europe, Asia Pacific and LAMEA. The Asia Pacific region acquired a substantial revenue share in the market in 2022. The rapidly rising rate of the senior population and increasing demand for improved healthcare facilities, especially in developing countries in the region, are some of the market drivers. The presence of big pharmaceutical industries like India and China will also boost the regional market growth. China is owing to the greater government spending on improving healthcare facilities within the region and the government's initiative to enhance the production of high-quality pharmaceuticals within the country.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Recent Strategies Deployed in Oncology Drugs Market

Partnerships, Collaborations, and Agreements:

Nov-2023: Astellas Pharma Inc. and Propella Therapeutics, Inc. announced the completion of a merger agreement, with Astellas acquiring Propella, a privately held biopharmaceutical company, utilized a proprietary platform combining medicinal chemistry with lymphatic targeting to develop new oncology drugs.

Sep-2023: Bristol Myers Squibb Company and Samsung Biologics, a South Korean biotechnology company, signed an agreement for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Under the new agreement, Samsung Biologics provided drug substance manufacturing at its latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea.

Sep-2023: F. Hoffmann-La Roche Ltd. expanded its collaboration with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies, enhancing research and innovation. The expanded agreement provided broader opportunities for collaboration in precision medicine, incorporating various companion diagnostics technologies like immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

2023-Sep: Merck & Co., Inc. announced strategic drug discovery collaborations with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., utilizing AI-driven design and discovery capabilities to advance research. The partnerships aimed to produce novel clinical development drug candidates with first-in-class and best-in-class potential in oncology, neurology, and immunology.

Sep-2023: Merck & Co., Inc., and the Institute of Cancer Research (ICR) renewed their strategic collaboration to discover and develop cancer therapeutics. Researchers from the institute's Centre for Cancer Drug Discovery collaborated with Merck to develop small-molecule inhibitors targeting a new class of cancer targets, with both parties contributing staff and financial resources for the partnership.

Jun-2023: Astellas Pharma Inc. and Cullgen Inc., a privately held biopharmaceutical company, came into collaboration and exclusive option agreement to discover innovative protein degraders. The partnership aimed to develop targeted protein degraders by combining Cullgen's uSMITE platform with novel E3 ligands and Astellas' drug discovery capabilities.

May-2023: Astellas Pharma Inc. and Sony Corporation, a conglomerate that specializes in the development, design, production, manufacture, and sale of an electronic equipment, collaborated to develop a novel Antibody-Drug Conjugate (ADC) platform in oncology, utilizing Sony's unique polymeric material, "KIRAVIATM Backbone." The goal was to selectively deliver anti-cancer drugs to target cells, enhancing efficacy while minimizing side effects. The research aimed to create high-performing ADCs with stable drug delivery and a high Drug-to-Antibody Ratio (DAR).

May-2023: Janssen Biotech, part of Johnson & Johnson's Janssen Pharmaceutical Companies, collaborated with Cellular Biomedicine Group, a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China, to develop and commercialize next-gen CAR T-cell therapies for B-cell malignancies. The investigational CD20-directed CAR-Ts exhibited promising responses in Phase 1 studies for relapsed/refractory non-Hodgkin's lymphoma in China, particularly in diffuse large B-cell lymphoma cases.

Feb-2023: AstraZeneca PLC expanded its partnership with Sophia Genetics, a data-driven medicine software company with headquarters in Lausanne, Switzerland, applying multimodal data management and analytics technology to oncology drug development. Using Sophia's DDM platform, they combined molecular data, imaging analysis, digital.

Jan-2023: AbbVie, Inc. and Immunome, Inc., a clinical-stage biopharmaceutical company, announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs from three specified tumour types using Immunome's Discovery Engine. The collaboration aimed to unlock novel cancer biology, potentially yielding multiple therapeutic candidates. The utilization of Immunome's Discovery Engine was anticipated to enhance AbbVie's existing oncology pipeline.

Nov-2022: F. Hoffmann-La Roche Ltd. entered a second collaboration and license agreement with Jnana Therapeutics, a biotech company using its next-gen chemoproteomics platform for discovering small molecule drugs. The collaboration aimed to address diseases with high unmet needs, covering multiple targets from various target classes.

Nov-2022: Pfizer Inc reached a settlement agreement with Glenmark Pharmaceuticals for the cancer treatment drug Axitinib Tablets (1 mg and 5 mg). The Mumbai-based drug maker and its US-based unit signed the settlement pact with Pfizer Inc.

Oct-2022: F. Hoffmann-La Roche Ltd. and Hookipa Pharma, a clinical stage company developing products to prevent and cure infectious diseases and cancer., forged a strategic partnership and license agreement for the development of HB-700 and an undisclosed arenaviral immunotherapy. Hookipa conducted research and initial Phase Ib clinical development for HB-700 to treat KRAS-mutated cancers. Upon trial completion, Roche obtained the right to develop and market the licensed products across various indications, subject to approval.

Sep-2022: Pfizer extended its partnership with CytoReason, a tech company developing a computational model of the human body, to use CytoReason's artificial intelligence technology for Pfizer's drug development programs. Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason's platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years.

Mar-2022: Novartis AG strategically collaborated with Lantheus Holdings, Inc., incorporating PYLARIFY® in prostate cancer clinical trials with Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Under the agreement, Lantheus supplied PYLARIFY for patient selection, and Novartis shared all PYLARIFY-related clinical imaging data with Lantheus.

Dec-2021: Novartis Pharma AG and BeiGene, Ltd. entered an option, collaboration, and license agreement for the development, manufacturing, and commercialization of BeiGene's TIGIT inhibitor ociperlimab in North America, Europe, and Japan. Additionally, BeiGene obtained rights to market and detail five approved Novartis oncology products-TAFINLAR (dabrafenib), MEKINIST (trametinib), VOTRIENT (pazopanib), AFINITOR (everolimus), and ZYKADIA (ceritinib)-across designated regions of China termed "broad markets."

Jul-2021: Pfizer Inc. collaborated with Arvinas, Inc., a biopharmaceutical company that develops protein degradation therapeutics., to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The collaboration leveraged Arvinas' targeted protein degradation leadership and Pfizer's global capabilities and breast cancer expertise, enhancing ARV-471's development and potential commercialization while advancing Arvinas' strategy.

Mar-2021: Novartis AG came into collaboration with Artios Pharma Limited (Artios) in a global research initiative, exploring and validating next-generation DNA Damage Response (DDR) targets to enhance Novartis' Radioligand Therapies (RLT). In the three-year partnership, Artios and Novartis conducted target discovery and validation, with Novartis selecting up to three exclusive DDR targets. Novartis obtained worldwide rights to utilize these targets with its RLTs.

Dec-2020: AbbVie, Inc. and Frontier Medicines, Corp. announced a global strategic collaboration to discover, develop, and commercialize innovative small molecule therapeutics against challenging protein targets. The collaboration utilized Frontier's chemo proteomics platform to identify small molecules for targeting novel E3 ligases, oncology, and immunology targets. Unlike conventional methods, this approach offered the potential to target a broader range of proteins.

Dec-2020: Pfizer Inc. and Myovant Sciences, helps women with uterine fibroids and endometriosis and men with prostate cancer by developing new medicines, collaborated to develop and commercialize relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in oncology and women's health in the U.S. and Canada. Pfizer gained an exclusive option for relugolix commercialization in oncology outside the U.S. and Canada, excluding specific Asian countries.

Oct-2020: Novartis AG partnered with Molecular Partners AG, a clinical-stage biopharmaceutical company based in Zurich, Switzerland, to develop and commercialize the anti-COVID-19 DARPin program, featuring candidates MP0420 and MP0423, aiming to expedite development using Molecular Partners' DARPin technologies and Novartis' expertise in drug development and commercialization in response to the urgent global need during the pandemic.

Sep-2020: AbbVie, Inc. and I-Mab, a global biotechnology company, signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody developed by I-Mab for treating various cancers. The agreement also included the potential expansion of collaboration to additional transformative therapies.

Jun-2020: AbbVie, Inc. and Genmab A/S, an international biotech company specializing in creation and development of differentiated antibody therapeutics for treatment of cancer., concluded a collaboration to jointly develop and commercialize three early-stage bispecific antibody candidates and explore future antibody therapeutics for cancer. This partnership combined Genmab's expertise with AbbVie's clinical experience and innovative platforms.

Jun-2020: Roche Pharma India, a subsidiary of F. Hoffmann-La Roche Ltd., extended its partnership with Cipla, a Mumbai-based multinational pharmaceutical company. This expanded collaboration included marketing and distribution of Roche's oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin), and rituximab (Ristova) in India. The agreement aimed to maintain Roche's focus on providing innovations in India's healthcare system and fostering collaboration with stakeholders for improved patient outcomes.

Product Launches and Product Expansions:

Jun-2023: AstraZeneca PPLC launched its groundbreaking cancer medication, IMJUDO (tremelimumab), in the UAE. This move positioned the UAE as one of the first countries in the Middle East to provide access to the medication, signifying a notable advancement in cancer treatment. The drug demonstrated promising results, extending progression-free survival and overall survival rates, leading to improved treatment outcomes and a higher quality of life for patients.

May-2022: F. Hoffmann-La Roche Ltd. introduced PHESGO, a drug for breast cancer treatment. PHESGO, the first fixed-dose formulation in oncology combining Perjeta and Herceptin with hyaluronidase, was administered via subcutaneous injection along with intravenous chemotherapy for early and metastatic breast cancer. The launch enhanced efficiency in healthcare systems, requiring less preparation and administration time, freeing up time for patients and healthcare professionals, and offering cost-saving benefits.

Acquisition and Mergers:

Oct-2023: Bristol Myers Squibb Company and Mirati Therapeutics, Inc. finalized a merger agreement, with Bristol Myers Squibb acquiring Mirati. Through this acquisition, Bristol Myers Squibb added KRAZATI, a significant lung cancer medicine, to its commercial portfolio and gained access to promising clinical assets for its oncology pipeline and combination strategies.

Apr-2023: Astellas Pharma Inc. and Iveric bio, Inc., a biopharmaceutical company focused on the discovery and development of novel treatment, entered a definitive agreement in which Astellas, through Berry Merger Sub, Inc., a wholly owned subsidiary of Astellas US Holding, Inc., acquired 100% of Iveric Bio's outstanding shares for $40.00 per share in cash, totalling approximately $5.9 billion in equity value. Iveric Bio became an indirectly wholly owned subsidiary of Astellas in the acquisition, considering approximately 148.2 million fully diluted outstanding shares of Iveric Bio common stock.

Jan-2023: Merck & Co., Inc. completed the acquisition of Imago Biosciences, Inc. at a cash purchase price of $36.00 per share. Following the merger, Imago became a wholly owned subsidiary of Merck, and its common stock ceased trading on the Nasdaq Global Market.

Dec-¬2022: Johnson & Johnson announced that it completed its acquisition of Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment. This acquisition marks another important step on Johnson & Johnson's path to accelerating growth in our MedTech business and delivering innovative medical technologies to more people around the world.

Oct¬-2022: AbbVie, Inc. acquired DJS Antibodies Ltd, a UK biotech company focusing on developing antibodies for challenging disease-causing proteins. DJS-002, their lead program, aimed at treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

Sep-2022: F. Hoffmann-La Roche Ltd. acquired Good Therapeutics, a US-based biopharmaceutical company, through a definitive merger agreement for an upfront cash payment of $250 million. The acquisition granted Roche rights to Good Therapeutics' conditionally active, PD-1-regulated IL-2 program and exclusive access to the platform technology for developing PD-1-regulated IL-2 receptor agonist therapies.

Jun-2022: Bristol Myers Squibb acquired Turning Point Therapeutics in a definitive merger agreement, expanding its oncology franchise with a best-in-class precision oncology asset. Giovanni Caforio, M.D., Board Chair, and Chief Executive Officer at Bristol Myers Squibb stated that the transaction bolstered their growth profile through strategic business development.

Oct-2021: Amgen, Inc. completed the acquisition of Teneobio, Inc., a biotechnology company that specializes in the development of human heavy chain antibodies, expanding its multispecific architectures and advancing the mission to develop transformative innovations for best-in-class products to serve patients.

Aug-2020: Johnson & Johnson acquired Momenta Pharmaceuticals, a biotechnology company, specializes in the in the characterization and process engineering of complex molecules., for approximately $6.5 billion in an all-cash transaction, enhancing Janssen Pharmaceutical Companies' leadership in immune-mediated diseases. The deal included global rights to nipocalimab (M281), a potentially best-in-class anti-FcRn antibody, providing opportunities to address various autoimmune diseases with substantial unmet medical needs.

Scope of the Study

Market Segments covered in the Report:

By Indication

Breast Cancer
Prostate Cancer
Lung Cancer
Stomach Cancer
Colorectal Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer

By Drug Class Type

Targeted Therapy
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Companies Profiled

AbbVie, Inc.
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Oncology Drugs Market, by Indication
- 1.4.2 Global Oncology Drugs Market, by Drug Class Type
- 1.4.3 Global Oncology Drugs Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar - 2023, Nov) Leading Players
4.4 Porter's Five Forces Analysis

Chapter 5. Global Oncology Drugs Market by Indication

5.1 Global Breast Cancer Market by Region
5.2 Global Prostate Cancer Market by Region
5.3 Global Lung Cancer Market by Region
5.4 Global Stomach Cancer Market by Region
5.5 Global Colorectal Cancer Market by Region
5.6 Global Liver Cancer Market by Region
5.7 Global Esophagus Cancer Market by Region
5.8 Global Cervical Cancer Market by Region
5.9 Global Kidney Cancer Market by Region
5.10. Global Bladder Cancer Market by Region
5.11 Global Other Cancer Market by Region

Chapter 6. Global Oncology Drugs Market by Drug Class Type

6.1 Global Targeted Therapy Market by Region
6.2 Global Immunotherapy (Biologic Therapy) Market by Region
6.3 Global Chemotherapy Market by Region
6.4 Global Hormonal Therapy Market by Region

Chapter 7. Global Oncology Drugs Market by Region

7.1 North America Oncology Drugs Market
- 7.1.1 North America Oncology Drugs Market by Indication
  - 7.1.1.1 North America Breast Cancer Market by Country
  - 7.1.1.2 North America Prostate Cancer Market by Country
  - 7.1.1.3 North America Lung Cancer Market by Country
  - 7.1.1.4 North America Stomach Cancer Market by Country
  - 7.1.1.5 North America Colorectal Cancer Market by Country
  - 7.1.1.6 North America Liver Cancer Market by Country
  - 7.1.1.7 North America Esophagus Cancer Market by Country
  - 7.1.1.8 North America Cervical Cancer Market by Country
  - 7.1.1.9 North America Kidney Cancer Market by Country
  - 7.1.1.10 North America Bladder Cancer Market by Country
  - 7.1.1.11 North America Other Cancer Market by Country
- 7.1.2 North America Oncology Drugs Market by Drug Class Type
  - 7.1.2.1 North America Targeted Therapy Market by Country
  - 7.1.2.2 North America Immunotherapy (Biologic Therapy) Market by Country
  - 7.1.2.3 North America Chemotherapy Market by Country
  - 7.1.2.4 North America Hormonal Therapy Market by Country
- 7.1.3 North America Oncology Drugs Market by Country
  - 7.1.3.1 US Oncology Drugs Market
    - 7.1.3.1.1 US Oncology Drugs Market by Indication
    - 7.1.3.1.2 US Oncology Drugs Market by Drug Class Type
  - 7.1.3.2 Canada Oncology Drugs Market
    - 7.1.3.2.1 Canada Oncology Drugs Market by Indication
    - 7.1.3.2.2 Canada Oncology Drugs Market by Drug Class Type
  - 7.1.3.3 Mexico Oncology Drugs Market
    - 7.1.3.3.1 Mexico Oncology Drugs Market by Indication
    - 7.1.3.3.2 Mexico Oncology Drugs Market by Drug Class Type
  - 7.1.3.4 Rest of North America Oncology Drugs Market
    - 7.1.3.4.1 Rest of North America Oncology Drugs Market by Indication
    - 7.1.3.4.2 Rest of North America Oncology Drugs Market by Drug Class Type
7.2 Europe Oncology Drugs Market
- 7.2.1 Europe Oncology Drugs Market by Indication
  - 7.2.1.1 Europe Breast Cancer Market by Country
  - 7.2.1.2 Europe Prostate Cancer Market by Country
  - 7.2.1.3 Europe Lung Cancer Market by Country
  - 7.2.1.4 Europe Stomach Cancer Market by Country
  - 7.2.1.5 Europe Colorectal Cancer Market by Country
  - 7.2.1.6 Europe Liver Cancer Market by Country
  - 7.2.1.7 Europe Esophagus Cancer Market by Country
  - 7.2.1.8 Europe Cervical Cancer Market by Country
  - 7.2.1.9 Europe Kidney Cancer Market by Country
  - 7.2.1.10 Europe Bladder Cancer Market by Country
  - 7.2.1.11 Europe Other Cancer Market by Country
- 7.2.2 Europe Oncology Drugs Market by Drug Class Type
  - 7.2.2.1 Europe Targeted Therapy Market by Country
  - 7.2.2.2 Europe Immunotherapy (Biologic Therapy) Market by Country
  - 7.2.2.3 Europe Chemotherapy Market by Country
  - 7.2.2.4 Europe Hormonal Therapy Market by Country
- 7.2.3 Europe Oncology Drugs Market by Country
  - 7.2.3.1 Germany Oncology Drugs Market
    - 7.2.3.1.1 Germany Oncology Drugs Market by Indication
    - 7.2.3.1.2 Germany Oncology Drugs Market by Drug Class Type
  - 7.2.3.2 UK Oncology Drugs Market
    - 7.2.3.2.1 UK Oncology Drugs Market by Indication
    - 7.2.3.2.2 UK Oncology Drugs Market by Drug Class Type
  - 7.2.3.3 France Oncology Drugs Market
    - 7.2.3.3.1 France Oncology Drugs Market by Indication
    - 7.2.3.3.2 France Oncology Drugs Market by Drug Class Type
  - 7.2.3.4 Russia Oncology Drugs Market
    - 7.2.3.4.1 Russia Oncology Drugs Market by Indication
    - 7.2.3.4.2 Russia Oncology Drugs Market by Drug Class Type
  - 7.2.3.5 Spain Oncology Drugs Market
    - 7.2.3.5.1 Spain Oncology Drugs Market by Indication
    - 7.2.3.5.2 Spain Oncology Drugs Market by Drug Class Type
  - 7.2.3.6 Italy Oncology Drugs Market
    - 7.2.3.6.1 Italy Oncology Drugs Market by Indication
    - 7.2.3.6.2 Italy Oncology Drugs Market by Drug Class Type
  - 7.2.3.7 Rest of Europe Oncology Drugs Market
    - 7.2.3.7.1 Rest of Europe Oncology Drugs Market by Indication
    - 7.2.3.7.2 Rest of Europe Oncology Drugs Market by Drug Class Type
7.3 Asia Pacific Oncology Drugs Market
- 7.3.1 Asia Pacific Oncology Drugs Market by Indication
  - 7.3.1.1 Asia Pacific Breast Cancer Market by Country
  - 7.3.1.2 Asia Pacific Prostate Cancer Market by Country
  - 7.3.1.3 Asia Pacific Lung Cancer Market by Country
  - 7.3.1.4 Asia Pacific Stomach Cancer Market by Country
  - 7.3.1.5 Asia Pacific Colorectal Cancer Market by Country
  - 7.3.1.6 Asia Pacific Liver Cancer Market by Country
  - 7.3.1.7 Asia Pacific Esophagus Cancer Market by Country
  - 7.3.1.8 Asia Pacific Cervical Cancer Market by Country
  - 7.3.1.9 Asia Pacific Kidney Cancer Market by Country
  - 7.3.1.10 Asia Pacific Bladder Cancer Market by Country
  - 7.3.1.11 Asia Pacific Other Cancer Market by Country
- 7.3.2 Asia Pacific Oncology Drugs Market by Drug Class Type
  - 7.3.2.1 Asia Pacific Targeted Therapy Market by Country
  - 7.3.2.2 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country
  - 7.3.2.3 Asia Pacific Chemotherapy Market by Country
  - 7.3.2.4 Asia Pacific Hormonal Therapy Market by Country
- 7.3.3 Asia Pacific Oncology Drugs Market by Country
  - 7.3.3.1 China Oncology Drugs Market
    - 7.3.3.1.1 China Oncology Drugs Market by Indication
    - 7.3.3.1.2 China Oncology Drugs Market by Drug Class Type
  - 7.3.3.2 Japan Oncology Drugs Market
    - 7.3.3.2.1 Japan Oncology Drugs Market by Indication
    - 7.3.3.2.2 Japan Oncology Drugs Market by Drug Class Type
  - 7.3.3.3 India Oncology Drugs Market
    - 7.3.3.3.1 India Oncology Drugs Market by Indication
    - 7.3.3.3.2 India Oncology Drugs Market by Drug Class Type
  - 7.3.3.4 South Korea Oncology Drugs Market
    - 7.3.3.4.1 South Korea Oncology Drugs Market by Indication
    - 7.3.3.4.2 South Korea Oncology Drugs Market by Drug Class Type
  - 7.3.3.5 Singapore Oncology Drugs Market
    - 7.3.3.5.1 Singapore Oncology Drugs Market by Indication
    - 7.3.3.5.2 Singapore Oncology Drugs Market by Drug Class Type
  - 7.3.3.6 Malaysia Oncology Drugs Market
    - 7.3.3.6.1 Malaysia Oncology Drugs Market by Indication
    - 7.3.3.6.2 Malaysia Oncology Drugs Market by Drug Class Type
  - 7.3.3.7 Rest of Asia Pacific Oncology Drugs Market
    - 7.3.3.7.1 Rest of Asia Pacific Oncology Drugs Market by Indication
    - 7.3.3.7.2 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type
7.4 LAMEA Oncology Drugs Market
- 7.4.1 LAMEA Oncology Drugs Market by Indication
  - 7.4.1.1 LAMEA Breast Cancer Market by Country
  - 7.4.1.2 LAMEA Prostate Cancer Market by Country
  - 7.4.1.3 LAMEA Lung Cancer Market by Country
  - 7.4.1.4 LAMEA Stomach Cancer Market by Country
  - 7.4.1.5 LAMEA Colorectal Cancer Market by Country
  - 7.4.1.6 LAMEA Liver Cancer Market by Country
  - 7.4.1.7 LAMEA Esophagus Cancer Market by Country
  - 7.4.1.8 LAMEA Cervical Cancer Market by Country
  - 7.4.1.9 LAMEA Kidney Cancer Market by Country
  - 7.4.1.10 LAMEA Bladder Cancer Market by Country
  - 7.4.1.11 LAMEA Other Cancer Market by Country
- 7.4.2 LAMEA Oncology Drugs Market by Drug Class Type
  - 7.4.2.1 LAMEA Targeted Therapy Market by Country
  - 7.4.2.2 LAMEA Immunotherapy (Biologic Therapy) Market by Country
  - 7.4.2.3 LAMEA Chemotherapy Market by Country
  - 7.4.2.4 LAMEA Hormonal Therapy Market by Country
- 7.4.3 LAMEA Oncology Drugs Market by Country
  - 7.4.3.1 Brazil Oncology Drugs Market
    - 7.4.3.1.1 Brazil Oncology Drugs Market by Indication
    - 7.4.3.1.2 Brazil Oncology Drugs Market by Drug Class Type
  - 7.4.3.2 Argentina Oncology Drugs Market
    - 7.4.3.2.1 Argentina Oncology Drugs Market by Indication
    - 7.4.3.2.2 Argentina Oncology Drugs Market by Drug Class Type
  - 7.4.3.3 UAE Oncology Drugs Market
    - 7.4.3.3.1 UAE Oncology Drugs Market by Indication
    - 7.4.3.3.2 UAE Oncology Drugs Market by Drug Class Type
  - 7.4.3.4 Saudi Arabia Oncology Drugs Market
    - 7.4.3.4.1 Saudi Arabia Oncology Drugs Market by Indication
    - 7.4.3.4.2 Saudi Arabia Oncology Drugs Market by Drug Class Type
  - 7.4.3.5 South Africa Oncology Drugs Market
    - 7.4.3.5.1 South Africa Oncology Drugs Market by Indication
    - 7.4.3.5.2 South Africa Oncology Drugs Market by Drug Class Type
  - 7.4.3.6 Nigeria Oncology Drugs Market
    - 7.4.3.6.1 Nigeria Oncology Drugs Market by Indication
    - 7.4.3.6.2 Nigeria Oncology Drugs Market by Drug Class Type
  - 7.4.3.7 Rest of LAMEA Oncology Drugs Market
    - 7.4.3.7.1 Rest of LAMEA Oncology Drugs Market by Indication
    - 7.4.3.7.2 Rest of LAMEA Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles

8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 Amgen, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Partnerships, Collaborations, and Agreements:
  - 8.4.5.2 Product Launches and Product Expansions:
- 8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
  - 8.5.5.2 Product Launches and Product Expansions:
  - 8.5.5.3 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Product Launches and Product Expansions:
  - 8.6.5.3 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental & Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Acquisition and Mergers:
- 8.7.6 SWOT Analysis
8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Partnerships, Collaborations, and Agreements:
  - 8.9.5.2 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional & Segmental Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 Recent strategies and developments:
  - 8.10.5.1 Partnerships, Collaborations, and Agreements:
- 8.10.6 SWOT Analysis

がん治療薬の世界市場規模、シェア、産業動向分析レポート：適応症別、薬剤クラス別、地域別展望と予測、2023年～2030年

Global Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

目次

第1章市場範囲と調査手法

第2章市場の概要

第3章市場概要

第4章競合分析 - 世界

第5章世界のがん治療薬市場：適応症別

第6章世界のがん治療薬市場：薬剤クラス別

第7章世界のがん治療薬市場：地域別

第8章企業プロファイル

第9章がん治療薬市場の勝利の必須条件

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Oncology Drugs Market by Indication

Chapter 6. Global Oncology Drugs Market by Drug Class Type

Chapter 7. Global Oncology Drugs Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives of Oncology Drugs Market

がん治療薬の世界市場規模、シェア、産業動向分析レポート：適応症別、薬剤クラス別、地域別展望と予測、2023年～2030年

Global Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

目次

第1章 市場範囲と調査手法

第2章 市場の概要

第3章 市場概要

第4章 競合分析 - 世界

第5章 世界のがん治療薬市場：適応症別

第6章 世界のがん治療薬市場：薬剤クラス別

第7章 世界のがん治療薬市場：地域別

第8章 企業プロファイル

第9章 がん治療薬市場の勝利の必須条件

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Oncology Drugs Market by Indication

Chapter 6. Global Oncology Drugs Market by Drug Class Type

Chapter 7. Global Oncology Drugs Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives of Oncology Drugs Market

第1章市場範囲と調査手法

第2章市場の概要

第3章市場概要

第4章競合分析 - 世界

第5章世界のがん治療薬市場：適応症別

第6章世界のがん治療薬市場：薬剤クラス別

第7章世界のがん治療薬市場：地域別

第8章企業プロファイル

第9章がん治療薬市場の勝利の必須条件